Oncology · Gastroesophageal CancerTrial Updateclinicalmid-term

FAST-GO Study Evaluates Physical Function in Gastroesophageal Cancer Patients Undergoing Chemotherapy

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/9/2026, 12:33:20 AM

Assessment confidence: 73% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FAST-GO study is crucial as it evaluates the impact of chemotherapy on the physical function of gastroesophageal cancer patients, which could significantly influence treatment protocols and patient management strategies. Insights gained may enhance competitive positioning among therapies in this therapeutic area. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 25 ranked evidence items (16 high-relevance).

Strategic Assessment

Understanding the effects of chemotherapy on physical function could inform supportive care strategies and enhance patient management approaches. The strongest clinical anchor is A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study (ClinicalTrials.gov), entity match (jonsson comprehensive cancer center). In Oncology · Gastroesophageal Cancer, 5 regulatory and 4 competitive items passed relevance filtering for Jonsson Comprehensive Cancer Center.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC. This study may provide insights into the quality of life and functional outcomes for patients, influencing treatment decisions and competitive positioning among therapies.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). Relevant agencies in corpus: FDA, MHRA. While the study may not directly affect regulatory approvals, it could inform future guidelines and recommendations for patient care in oncology.

Key Opportunities

The findings could lead to shifts in treatment preferences, impacting market share for existing therapies and potentially opening avenues for new supportive care products.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Upside for Jonsson Comprehensive Cancer Center may improve if An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Jonsson Comprehensive Cancer Center may improve if A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor results for changes in physical function metrics and any subsequent impact on treatment protocols.
Timeline shift beyond mid term would change urgency.
Outcome from Ongoing | Cancer Accelerated Approvals would change the regulatory/clinical read.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
MHRA authorises gemcitabine delivery system for adults with BCG-unresponsive high-risk non-muscle invasive bladder cancer
MHRAhigh relevance
Regulatory pathway relevance (bla)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAhigh relevance
Moderate corpus alignment
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source

A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study
ClinicalTrials.govhigh relevance
Entity match (jonsson comprehensive cancer center)
FDA document
View source
Effects of Nursing-led Communication Using Mobile Health Information in Breast Cancer Patients Undergoing Concurrent Chemotherapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Far Infrared Rays and Transcutaneous Electrical Nerve Stimulation on Short Term Prognosis of Head and Neck Cancer Patients Receiving Curative Treatment
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
PG2 Breast Cancer Evaluation in Adjuvant Medicine-Survival Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Risk Stratification and Proactive Nursing Intervention for Acute Kidney Injury Following Interventional Therapy in Patients With Liver Cancer
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer)
NCI Trials CD19/CD22 CAR T Cells for Refractory B Cell Malignancies in Young Patients
Humanexa Signalsmedium relevance
Moderate corpus alignment
SINGLE-AF Trial Evaluates DOACs in Intermediate Stroke Risk Atrial Fibrillation Patients
Humanexa Signalsmedium relevance
Moderate corpus alignment

Effects of sub-anesthetic doses of esketamine on immune function and postoperative negative emotions in acoustic neuroma patients: a randomized clinical trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
A qualitative study exploring discharge readiness experiences among patients with esophageal cancer undergoing esophagectomy.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Unveiling the cognitive fog in lung cancer patients: non-invasive exploration of blood-brain barrier disruption and brain structural changes.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Type 2 diabetes remission in gynaecologic oncology patients completing an acute preoperative weight loss protocol: a case series.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Jonsson Comprehensive Cancer Center
gastroesophageal cancer therapies

Commercial impact

medium

The findings could lead to shifts in treatment preferences, impacting market share for existing therapies and potentially opening avenues for new supportive care products.

Regulatory impact

low

While the study may not directly affect regulatory approvals, it could inform future guidelines and recommendations for patient care in oncology.

What to watch

Monitor results for changes in physical function metrics and any subsequent impact on treatment protocols.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.